As reported in Biopharma Dive, Regeneron Pharmaceuticals on Friday secured an early approval from the Food and Drug Administration for a cancer immunotherapy that works in the same fashion as Merck & Co’s Keytruda, adding yet another contender to the fast-growing immuno-oncology field.
Regeneron’s drug, called Libtayo, is a latecomer, arriving years behind Keytruda and Bristol-Myers Squibb’s Opdivo, both of which target the same PD-1 protein. Three other approved immunotherapies block a related protein called PD-L1.
Libtayo won’t face any competition in its first indication for metastatic cutaneous squamous cell carcinoma (CSCC), a disease for which none of the other five drugs are approved. Yet Regeneron’s ambitions— and that of its development partner Sanofi— are broader, with plans to expand into more contested markets.Source: Biopharma Drive